医药前沿
醫藥前沿
의약전연
YIAYAO QIANYAN
2015年
7期
117-118
,共2页
心力衰竭%芪苈强心胶囊%血浆脑钠肽%高敏C反应蛋白(hs-CRP)
心力衰竭%芪藶彊心膠囊%血漿腦鈉肽%高敏C反應蛋白(hs-CRP)
심력쇠갈%기력강심효낭%혈장뇌납태%고민C반응단백(hs-CRP)
Heart failure%Stilbene Li strong heart capsule%Plasma brain natriuretic peptide%High-sensitivity c-reactive protein (hs - CRP)
目的：观察芪苈强心胶囊治疗冠心病心力衰竭临床疗效。方法：随机把冠心病心力衰竭的患者78例分为观察组(39例，西医常规治疗+芪苈强心胶囊)和对照组(39例，西医常规治疗)，治疗2周后比较两组患者心功能、血浆NT-proBNP及hs-CRP水平。结果：治疗后观察组血浆NT-proBNP及hs-CRP水平低于对照组(P<0.05)，临床疗效优于对照组(P<0.05)。结论：在西医常规治疗基础上加用芪苈强心胶囊治疗冠心病心力衰竭疗效显著，改善预后。
目的：觀察芪藶彊心膠囊治療冠心病心力衰竭臨床療效。方法：隨機把冠心病心力衰竭的患者78例分為觀察組(39例，西醫常規治療+芪藶彊心膠囊)和對照組(39例，西醫常規治療)，治療2週後比較兩組患者心功能、血漿NT-proBNP及hs-CRP水平。結果：治療後觀察組血漿NT-proBNP及hs-CRP水平低于對照組(P<0.05)，臨床療效優于對照組(P<0.05)。結論：在西醫常規治療基礎上加用芪藶彊心膠囊治療冠心病心力衰竭療效顯著，改善預後。
목적：관찰기력강심효낭치료관심병심력쇠갈림상료효。방법：수궤파관심병심력쇠갈적환자78례분위관찰조(39례，서의상규치료+기력강심효낭)화대조조(39례，서의상규치료)，치료2주후비교량조환자심공능、혈장NT-proBNP급hs-CRP수평。결과：치료후관찰조혈장NT-proBNP급hs-CRP수평저우대조조(P<0.05)，림상료효우우대조조(P<0.05)。결론：재서의상규치료기출상가용기력강심효낭치료관심병심력쇠갈료효현저，개선예후。
Objective Observe the stilbene Li strong heart capsule treatment of coronary heart disease (CHD) heart failure clinical curative effect.Methods Randomly divided 78 patients with heart failure of coronary artery disease into observation group and control group, 2 weeks after treatment compared two groups of patients with cardiac function, plasma NT - proBNP and hs - CRP levels.Results Observation group after treatment plasma NT - proBNP and hs - CRP levels lower than the control group (P < 0.05), the clinical curative effect is better than that of control group (P < 0.05).Conclusions On the basis of conventional western medicine therapy combined with stilbene Li strong heart capsule in treatment of coronary heart disease (CHD) heart failure curative effect significantly, improve the prognosis.
